Sunzen Biotech on track to return to the black

Top management: Teo (left) and Ching at the group’s headquarter in Shah Alam. They are very positive about Sunzen’s business outlook.

Sunzen Biotech Bhd is on track to break even this year and aims to achieve profitability in 2022, after incurring losses for three years, according to group managing director and CEO Teo Yek Ming.

Teo tells StarBizWeek that in the near term, the group is optimistic about growing profits for its traditional Chinese medicine, herbal health foods and beverages and bird’s nest segment as well as the recently acquired small and medium enterprise loan financing unit.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 48
Cxense type: NA
User access status: 0
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In Business News

Bank Negara international reserves fall to US$114bil as at March 15
SEMI: Global fab equipment spending to rise to US$92bil in 2024
KLCI climbs higher for second consecutive day
Oil slips on surprise US inventory build; Fed rate decision eyed
Bursa Malaysia inks collaboration with UMW, Maybank to roll out centralised sustainability platform
Philippine’s billionaire Frank Lao buys 35% stake in Malaysian coffee shop Zus
Kenanga IB wins seven awards at the Bursa Excellence Awards 2022
Fed's Powell faces political storm, policy minefield over SVB oversight
Bursa stays positive as attention shifts to the Fed
UOB Malaysia rolls out expanded sustainable solar financing programme

Others Also Read